Gilgamesh Pharmaceuticals has commenced subject dosing in a Phase IIa clinical trial of GM-1020 to treat major depressive disorder (MDD).
This clinical trial aims to evaluate the safety, tolerability, and efficacy of GM-1020 given as single and multiple oral doses.
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The study is designed as a randomised, two-part, controlled trial, starting with an initial placebo-controlled crossover phase, followed by a two-week multiple-dose period.
Gilgamesh anticipates that initial data from the Phase IIa trial will be available in the second half of this year.
An orally bioavailable NMDA receptor antagonist, GM-1020 is claimed to enhance upon established NMDA receptor antagonists by combining their quick and strong clinical efficacy with oral dosing and an enhanced safety/tolerability profile.
Gilgamesh founder and CEO Jonathan Sporn said: “Current treatments which block the serotonin transporter can take four to six weeks to show even a limited benefit and have significant and often limiting side effects, including blunted emotions, weight gain, sleep disturbance, and sexual dysfunction.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIn addition to GM-1020, Gilgamesh is advancing another asset, GM-2505, through Phase II trials for MDD.
In March, the company received a substantial boost with a multi-year $14m grant from the US National Institute on Drug Abuse to develop GM-3009, a cardiac-safe ibogaine analogue for treating substance use disorders.
The grant will provide non-dilutive funding to back IND-enabling toxicology studies, GMP manufacturing, and execute Phase I/Ib clinical trials of GM-3009 in healthy volunteers and opioid use disorder patients.
In December 2023, Gilgamesh stated its plans to initiate a Phase IIa trial of GM-2505 in Q1 2024.
